Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.42 |
| ▸ | CFTR | P13569 | 2/20 | 0.41 |
| ▸ | AGBL2 | Q5U5Z8 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16346244 | 0.86 | L3MBTL1 (0.45) | SMN1; SMN2AGBL2ALDH1A1MAPTGAA | |
| SCHEMBL31233701 | 0.81 | NOTUM (0.49) | SMN1; SMN2MAPK1NOTUMCFTRAGBL2 | |
| SCHEMBL30849372 | 0.81 | KDM4E (0.40) | SMN1; SMN2MAPK1AGBL2LMNAALDH1A1 | |
| SCHEMBL30481800 | 0.80 | AGBL2 (0.50) | SMN1; SMN2MAPK1NOTUMCFTRAGBL2 | |
| SCHEMBL16389694 | 0.80 | AGBL2 (0.50) | SMN1; SMN2MAPK1NOTUMCFTRAGBL2 | |
| SCHEMBL22208505 | 0.79 | MAPK1 (0.47) | SMN1; SMN2MAPK1NOTUMCFTRAGBL2 | |
| SCHEMBL30745103 | 0.79 | CYP4F2 (0.40) | MAPK1LMNAALDH1A1MAPTKDM4E | |
| SCHEMBL289465 | 0.79 | CYP4F2 (0.40) | MAPK1LMNAALDH1A1MAPTKDM4E | |
| SCHEMBL24391510 | 0.78 | AGBL2 (0.49) | SMN1; SMN2MAPK1NOTUMCFTRAGBL2 | |
| SCHEMBL30402328 | 0.78 | ALDH1A1 (0.40) | SMN1; SMN2MAPK1LMNAALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3778598-A2 | PESTICIDALLY ACTIVE BI- OR TRICYCLIC HETEROCYCLES WITH SULFUR CONTAINING SUBSTITUENTS | SYNGENTA PARTICIPATIONS AG (CH) | 2021-02-17 | — | — | EP | disclosed |
| EP-3778599-A2 | PESTICIDALLY ACTIVE BI- OR TRICYCLIC HETEROCYCLES WITH SULFUR CONTAINING SUBSTITUENTS | SYNGENTA PARTICIPATIONS AG (CH) | 2021-02-17 | — | — | EP | disclosed |
| EP-3016949-B1 | PESTICIDALLY ACTIVE BI- OR TRICYCLIC HETEROCYCLES WITH SULFUR CONTAINING SUBSTITUENTS | SYNGENTA PARTICIPATIONS AG (CH) | 2020-05-13 | — | — | EP | disclosed |
| US-20160255837-A1 | PESTICIDALLY ACTIVE BI- OR TRICYCLIC HETEROCYCLES WITH SULFUR CONTAINING SUBSTITUENTS | SYNGENTA PARTICIPATIONS AG (CH) | 2016-09-08 | — | — | US | disclosed |
| US-20160255837-A1 | PESTICIDALLY ACTIVE BI- OR TRICYCLIC HETEROCYCLES WITH SULFUR CONTAINING SUBSTITUENTS | SYNGENTA PARTICIPATIONS AG (CH) | 2016-09-08 | — | — | US | disclosed |
| WO-2015000715-A1 | PESTICIDALLY ACTIVE BI- OR TRICYCLIC HETEROCYCLES WITH SULFUR CONTAINING SUBSTITUENTS | SYNGENTA PARTICIPATIONS AG (CH) | 2015-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160255837-A1 | PESTICIDALLY ACTIVE BI- OR TRICYCLIC HETEROCYCLES WITH SULFUR CONTAINING SUBSTITUENTS | DDT, TST, SCLY | SMN1; SMN2 1669/4885MAPK1 4388/4885NOTUM 448/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.